Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

701.23 +18.30 (+2.68%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly. 
Via Investor's Business Daily
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity. 
Via Stocktwits
Topics Earnings
Has Eli Lilly Stock Peaked?
Via The Motley Fool
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, Jan. 13, 2024 MSFT, APLD, RGTI, LLY, TSLA were among the stocks trending with investors. 
Via Benzinga
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report. 
Via Talk Markets
Topics Economy Stocks / Equities
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Smart Money Is Betting Big In LLY Options
 
Via Benzinga
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation among investors. 
Via Benzinga
Topics Economy
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections
The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches. 
Via Stocktwits
Topics Earnings
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. 
Via Investor's Business Daily
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and Zepbound. The 2025 outlook forecasts up to $61 billion. 
Via Benzinga
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down. 
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline. 
Via Benzinga
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
Moncton, New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on... 
Via Newsfile
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
How Richard DiMarchi Revolutionized Diabetes Treatment
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi. 
Via Investor's Business Daily
3 Stocks to Buy for 2025 That Are Practically Money Machines
Via The Motley Fool
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Israel Englander's Millennium Management has made sweeping adjustments to its portfolio, including a remarkable 91,046.15% increase in Alibaba Group Holding Ltd. (NYSE:BABA) call options and a 94.69%... 
Via Benzinga
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
3 Trends To Watch
Hot topics for 2025 and why. 
Via Talk Markets
Topics Stocks / Equities
New Alphabet CFO Expected To Make Bigger Impact In 2025. Is Google Stock A Buy?
Google stock posted a big gain in 2024 but AI-driven competition in the internet search business and DoJ antitrust cases still loom. 
Via Investor's Business Daily
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.